Apogee Therapeutics (APGE) Accumulated Depreciation & Amortization (2024 - 2026)

Apogee Therapeutics (APGE) has 3 years of Accumulated Depreciation & Amortization data on file, last reported at -$2.2 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization rose 48.64% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.2 million (up 48.64% YoY) and the FY2025 annual result came in at -$2.6 million, down 138.41% from the prior year.
• Accumulated Depreciation & Amortization climbed to -$2.2 million in Q1 2026 per APGE's latest filing, from -$2.6 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at -$1.1 million in Q4 2024 and bottomed at -$5.0 million in Q2 2025.
• The 3-year median for Accumulated Depreciation & Amortization is -$2.6 million (2025), against an average of -$3.0 million.
• The widest annual swing landed in 2025, when Accumulated Depreciation & Amortization slumped 264.51%; it then soared 48.64% in 2026.
• Tracing APGE's Accumulated Depreciation & Amortization over 3 years: stood at -$1.1 million in 2024, then tumbled by 138.41% to -$2.6 million in 2025, then grew by 15.61% to -$2.2 million in 2026.
• Per Business Quant, the three latest APGE Accumulated Depreciation & Amortization figures stand at -$2.2 million (Q1 2026), -$2.6 million (Q4 2025), and -$4.3 million (Q3 2025).

Peer Comparison